Arrowhead Research | ARWR - Cash And Equivalent

Stock Price
67.39
Daily Change
-0.67 -0.98%
Monthly
5.49%
Yearly
232.46%
Q1 Forecast
67.19

Arrowhead Research reported $88.71M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Agios Pharmaceuticals USD 92.71M 11.84M Sep/2025
Alnylam Pharmaceuticals USD 1.49B 376.56M Sep/2025
Arrowhead Research USD 88.71M 41.09M Sep/2025
Incyte USD 2.93B 508.08M Sep/2025
Ionis Pharmaceuticals USD 2.24B 1.94B Sep/2025
Ligand Pharmaceuticals USD 664.52M 596.85M Sep/2025
Merck USD 18.17B 10.16B Sep/2025
Moderna USD 1.13B 147M Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Sarepta Therapeutics USD 613.08M 102.48M Sep/2025
TG Therapeutics USD 178.32M 100.54M Sep/2025
Ultragenyx Pharmaceutical USD 202.51M 36.4M Sep/2025
Vertex Pharmaceuticals USD 6.29B 95.8M Sep/2025
Xencor USD 28.29M 16.15M Sep/2025